Managers / Q4 2022 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $266M in U.S.-listed holdings across 13 positions for Q4 2022.
Its largest position, ARWR, represents 16.8% of the portfolio.
Compared with Q3 2022, the fund opened 0 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 55.7% · $148M
- ETP · 15.6% · $42M
- ADR · 14.6% · $39M
- Other · 14.1% · $37M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SPROSPERO THERAPEUTICS INC | SOLD OUT | −3.40M | 0 | −$7M | $0 |
| FDMT4D MOLECULAR THERAPEUTICS IN | SOLD OUT | −3.6K | 0 | −$29,000 | $0 |
| KYMRKYMERA THERAPEUTICS INC | ADDED | +299.2K | 629.4K | +$9M | $16M |
| QUREUNIQURE NV | TRIMMED | −216.6K | 624.9K | −$2M | $14M |
| PIERIS PHARMACEUTICALS INC | ADDED | +516.6K | 4.55M | +$92,991 | $5M |
| BLUEPRINT MEDICINES CORP | ADDED | +57.5K | 581.8K | −$9M | $25M |
| ARWRARROWHEAD PHARMACEUTICALS IN | TRIMMED | −115.0K | 1.10M | +$4M | $45M |
| RGNXREGENXBIO INC | TRIMMED | −70.0K | 897.7K | −$5M | $20M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 16.81% | $45M | 1.10M |
| 2 | BLUEPRINT MEDICINES CORP | COM | 9.57% | $25M | 581.8K |
| 3 | ARVNARVINAS INChistory → | COM | 8.66% | $23M | 673.9K |
| 4 | MERUS N V | COM | 8.32% | $22M | 1.43M |
| 5 | RGNXREGENXBIO INChistory → | COM | 7.65% | $20M | 897.7K |
| 6 | SLNSILENCE THERAPEUTICS PLChistory → | ADS | 7.36% | $20M | 1.28M |
| 7 | KYMRKYMERA THERAPEUTICS INChistory → | COM | 5.90% | $16M | 629.4K |
| 8 | AMRYT PHARMA PLC | SPONSORED ADS | 5.76% | $15M | 2.10M |
| 9 | QUREUNIQURE NVhistory → | SHS | 5.32% | $14M | 624.9K |
| 10 | GMABGENMAB A/Shistory → | SPONSORED ADS | 3.87% | $10M | 242.8K |
| 11 | ARGXARGENX SEhistory → | SPONSORED ADR | 3.42% | $9M | 24.0K |
| 12 | PIERIS PHARMACEUTICALS INC | COM | 1.78% | $5M | 4.55M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.